News for ADTX Stock

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™ Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025 Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection Evofem Reports Fourth Consecutive Year of Net Sales Growth Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025 Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025 Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S. Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders Evofem Secures Investor Support for Proposed Merger through Voting Agreements Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter Evofem Biosciences Announces Financial Results for the First Quarter of 2024 CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally Aditxt, Inc. to Present at 8th Annual Dawson James Conference Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023 Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023 Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023 Aditxt, Inc.’s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan Aditxt Issues Shareholder Update Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc. Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering Aditxt Announces Closing of $20.0 Million Public Offering Aditxt Announces Pricing of $20.0 Million Public Offering Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022 Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials Premier Medical Laboratory Services Now Offering AditxtScore™ Personalized Immune Test for COVID-19 Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th Aditxt to Participate in the 2022 Virtual Growth Conference Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron Aditxt, Inc. to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25th-27th, 2022 Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use Aditxt Signs Share Exchange Agreement to Acquire AiPharma Aditxt, Inc. Signs Non-Binding Letter of Intent to Acquire Point-of-Care Diagnostic Technology Development Company Aditxt Announces Closing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants Aditxt Extends the Timeline to Sign the Definitive Agreement to Acquire AiPharma Global to December 16, 2021 Aditxt Announces Pricing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants Led by Leading Healthcare Investor Aditxt Announces Proposed Public Offering of Common Stock and Warrants The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff’s Office, to Become First in the Nation to Deploy AditxtScore™ for Immune Scoring for its Employees and First Responders Aditxt Webinar at 2pm ET to Explore PRESECO Results Aditxt Provides an Update Regarding its Target Acquisition AiPharma Global Holdings LLC Aditxt Partners With CLX Health to Offer AditxtScore™ for COVID-19 Immune Monitoring Service Through CLX’s TrustAssure™ Platform Aditxt Announces Closing of $4.25 Million Public Offering Aditxt to Present at the Dawson James 6th Annual Small Cap Growth Conference in Florida on October 21, 2021 Aditxt Announces Pricing of $4.25 Million Public Offering Aditxt to Present at the LD Micro Main Event in Los Angeles on October 13, 2021 AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda That Has Treated Over 1.5M COVID-19 Patients Since The Outbreak. Aditxt Signs a Transaction Agreement to Acquire AiPharma, Rights Holder of Antiviral Tablet Avigan/Reeqonus/Qifenda Used in the Treatment of Over 1.5 Million COVID-19 Patients Outside the U.S. and Canada Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization Aditxt, Inc. and SphereDX Launch AditxtScore™ for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots Aditxt Announces Closing of $11 Million Registered Direct Offering, and Funding of Bridge Loan Satisfying a Key Term of its Letter of Intent for Planned Acquisition of Commercial Stage Pharma Company with Anti-Viral COVID-19 Therapy Aditxt Announces Pricing of $11.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19 Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic Aditxt Provides Update on AditxtReprogramming’s™ Apoptotic DNA Immunotherapy Therapeutic Platform Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19 Aditxt Opens its First High-Capacity Immune Monitoring Center in Richmond, VA Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors Aditxt Set to Join Russell Microcap® Index Aditxt Signs Channel Partner Agreement with Meridian HSN to Make AditxtScore™ for COVID-19 Available to its Network of Healthcare Provider Partners Aditxt to Establish State-of-the-Art Immune Monitoring Center in Richmond, VA Aditxt Therapeutics Names Sunny Uberoi as its first Chief Communications Officer HealthBar Becomes AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring to Complement its Concierge and Drive-Thru Testing Services Collection Sites, LLC Named AditxtScore™ Channel Partner to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring through its Mobile Testing Centers Aditxt to Initiate First-In-Human Clinical Trials with its Therapeutics Programs in Psoriasis by Year-End Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring with its Walk-In, Concierge, and Pre-Flight Services Immunologist and Clinical Transplant Expert, Dolly B. Tyan, PhD, Joins Aditxt as Senior VP of Clinical Development - Transplantation Aditxt Secures $5 Million Financing to Scale AditxtScore™ Operational Capacity AditxtScore™ Immune Monitoring Service Will be Operational on February 1st Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service Aditxt to Present at the 13th Annual LD Micro Main Event Conference Physician and Media Personality Dr. Drew and Aditxt CEO to Reveal and Discuss Their Personal AditxtScore™ for COVID-19 Results During AditxtEngage™ Live Event on Tuesday, December 1st at 10:00 am ET Aditxt Appoints Anthony Voorhies as Head of Business Development for AditxtScore™ Aditxt Secures CLIA Certification for AditxtScore™ Laboratory Operations in Richmond, VA, and Plans to Launch AditxtScore™ for COVID-19 as a Lab Developed Test (LDT) Aditxt Provides Business Update and Files Third Quarter 2020 10-Q Aditxt Announces First AditxtEngage™ Event, Continuing Series of Investor Opportunities to Engage with Company Former Chief Medical Officer and Assistant Secretary for Health Affairs of the U.S. Department of Homeland Security, Dr. Jeffrey Runge, Appointed to Aditxt Board of Directors Aditx Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference Aditx Therapeutics Announces Closing of Upsized $9.6 Million Follow-On Public Offering Physician and Media Personality Dr. Drew Pinsky, Dr. Drew, Joins Aditx Therapeutics as Senior Advisor to AditxtScore™ for Scoring the Immune System Aditx Therapeutics to Present at The LD 500 Virtual Conference Former President of the Global Business Unit at Schering AG, Dr. Joachim-Friedrich Kapp, MD, PhD, to Lead Aditx Therapeutics Clinical Development, Autoimmunity Aditxt Introduces AditxtScore™ for COVID-19 and Announces the Completion of Validation Studies by Stanford Blood Center Former CFO of BlackRock Capital Investment Corporation and AIG Capital Partners' Global Emerging Markets Group Corinne Pankovcin, Joins Aditx Therapeutics as Chief Financial Officer CORRECTION: Aditx Therapeutics, Inc. (Aditxt) Announces Closing of Initial Public Offering Aditx Therapeutics, Inc. (Aditxt) Announces Pricing of Initial Public Offering Aditxt to Present at Zooming with LD CEO, CIO, and Senior Advisors of Aditxt Complete Conversion of ~$1.1 Million in Accrued Compensation into Restricted IPO Units Aditx Therapeutics, Inc. (Aditxt) Announces Closing of Initial Public Offering